Abstract
The systematic identification of infectious, yet unreported, individuals is critical for the containment of the COVID-19 pandemic. We present a strategy for identifying the location, timing and extent of testing that maximizes information gain for such infections. The optimal testing strategy relies on Bayesian experimental design and forecasting epidemic models that account for time dependent interventions. It is applicable at the onset and spreading of the epidemic and can forewarn for a possible recurrence of the disease after relaxation of interventions. We examine its application in Switzerland and show that it can provide timely and systematic guidance for the effective identification of infectious individuals with finite testing resources. The methodology and the open source code are readily adaptable to countries around the world.
We present a strategy for the optimal allocation of testing resources in order to detect COVID-19 infections in a country’s population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge funding by ETH Zurich and computing resources by the Swiss Supercomputing center (CSCS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
It's a computational study/theoretical work with no risk involved for anyone.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available in the manuscript or the Supplementary Materials.
